Findings
Introduction
Patients and controls
Methods
Results
Gene | Exon/intron | Nucleotide change | Aminoacid change | LC n = 175 OR (95% CI) | MPT-LC n = 115 OR (95% CI) | MPT n = 68 OR (95% CI) | Controls n = 506 |
---|---|---|---|---|---|---|---|
RAD50
| Ex. 4 | c.379G>A | p.V127I | 2 | - | - | 2 |
2.91 (0.41-20.85) | |||||||
Ex. 7 | c.943G>T | p.V315L | - | 2 | - | 1 | |
8.96 (0.81-99.68) | |||||||
Ex. 25 | c.3876C>T | - | 1 | - | - | 0/180 | |
8.71 (0.35-215) | |||||||
MRE11
| Int. 16 | c.1783-86delAG | - | 39 | 18 | 20 | 61/279 |
1.03 (0.65-1.62) | 0.66 (0.37-1.18) | 1.49 (0.82-2.69) |
Genotype/allele | Controls n (%) | LC n (%) | OR (95% CI) | MPT-LC n (%) | OR (95% CI) | MPT n (%) | OR (95% CI) |
---|---|---|---|---|---|---|---|
GG | 233 (47) | 87 (50) | 1* | 50 (44) | 1* | 24 (35) | 1* |
GA | 195 (40) | 69 (39) | 1.06 (0.74-1.53) | 57 (50) | 0.73 (0.48-1.12) | 38 (56) |
0.53 (0.31-0.92)
†
|
AA | 66 (13) | 19 (11) | 1.30 (0.74-2.29) | 8 (6) | 1.78 (0.80-3.92) | 6 (9) | 1.13 (0.44-2.89) |
GA+AA | 261 (52) | 88 (50) | 1.11 (0.78-1.56) | 65 (57) | 0.86 (0.57-1.30) | 44 (65) | 0.61 (0.36-1.04) |
G | 661 (66) | 243 (69) | 1* | 157 (68) | 1* | 86 (63) | 1* 0.85 |
A | 327 (34) | 107 (31) | 1.12 (0.87-1.46) | 73 (22) | 1.06 (0.78-1.45) | 50 (37) | (0.59-1.24) |